Clinical trials: Apixaban, completed
Healthy Volunteers
Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets.
- Trial name
- NCT03509883
- Testing
- Drug: Apixaban sprinkle capsules, Experimental: Apixaban tablets followed by apixaban sprinkle capsules
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke, Intracranial Hemorrhages
Novel Oral Anticoagulants in Stroke Patients
The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs.
- Trial name
- NOACISP (NCT02353585)
- Where
- Switzerland
- Volunteers
- 1,050 people
- Sponsor
- University Hospital, Basel, Switzerland
Nephrotic Syndrome, Thromboembolic Disease
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.
- Trial name
- CAPTAIN (NCT04850378)
- Testing
- Dalteparin, Apixaban
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Aarhus
N/A - Healthy Subjects
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
- Trial name
- NCT02262533
- Testing
- Apixaban, Atenolol
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study
Several new oral direct anticoagulants have been recently marketed. However, only a few, limited, studies have provided data about the pharmacology of new oral direct anticoagulants in older persons.
- Trial name
- ADAGE (NCT02464488)
- Testing
- Plasma drug concentrations
- Where
- 2 sites in France
- Volunteers
- 232 people
- Sponsor
- Hôpital Charles Foix
Venous Thrombosis
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis…
- Trial name
- NCT00633893
- Testing
- Apixaban
- Where
- 428 sites in United States, Argentina and 27 more
- Volunteers
- 2,711 people
- Sponsor
- Bristol-Myers Squibb
Embolic Stroke of Undetermined Source
Apixaban for Treatment of Embolic Stroke of Undetermined Source
Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active controlled, efficacy study (phase III)
- Trial name
- ATTICUS (NCT02427126)
- Testing
- Apixaban, Aspirin
- Where
- 16 sites in Germany
- Volunteers
- 352 people
- Sponsor
- University Hospital Tuebingen
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Pulmonary Embolism Acute, Venous Thromboembolism (VTE)
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a…
- Trial name
- APIX-PE (Apixa (NCT07774273)
- Testing
- Drug: Apixaban, Drug: Rivaroxaban
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- Combined military hospital lahore
Anticoagulants and Thrombotic Disorders
Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients
Direct oral anticoagulants (DOACs) are now recommended as a first-line option in cancer patients with venous thromboembolism or atrial fibrillation.
- Trial name
- EPRAPAC (NCT05819736)
- Testing
- Monitoring
- Where
- France
- Volunteers
- 193 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Anticoagulation
Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden
This will be a retrospective cohort study using national register linkage data (including prescription, inpatient, mortality, and socioeconomic data). The study period will be from May 29, 2013 to June 30, 2015.
- Trial name
- NCT02492828
- Volunteers
- 41,000 people
- Sponsor
- Bristol-Myers Squibb
Post-Operative Atrial Fibrillation
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to…
- Trial name
- ATLAS (NCT02701062)
- Testing
- AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
- Where
- 22 sites in United States
- Volunteers
- 562 people
- Sponsor
- AtriCure, Inc.
Non-valvular Atrial Fibrillation
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm
There is a need to determine actual compliance of direct oral anticoagulants and how to improve this to reduce risk of stroke in patients with atrial fibrillation.
- Trial name
- BOAT OAR (NCT03515083)
- Testing
- Alive Cor Kardia mobile electrocardiogram monitor
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Saint Luke's Health System
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban.
- Trial name
- COBRRA Pilot (NCT02559856)
- Testing
- Apixaban, Rivaroxaban
- Where
- 4 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Ottawa Hospital Research Institute
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Atrial Fibrillation, Atrial Tachycardia
Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.
Catheter ablation of atrial fibrillation (AF) or left atrial tachycardia (GAD) is usually performed in patients treated with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) that are increasingly used.
- Trial name
- FACADO (NCT05802576)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation
Medical Need of OAC Reversal
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
- Trial name
- NCT03254147
- Testing
- warfarin, dabigatran, Apixaban
- Where
- Japan
- Volunteers
- 53,969 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment, Dementia, Mild
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia.
- Trial name
- EVANTHEA (NCT05894954)
- Testing
- Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alzheimer's Prevention and Reversal Project, Inc.
Ischemia, Anticoagulants
Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization
the Aim of the work is to compare the effect of CAT (Clopidogrel aspirin therapy) and AAT (Apixiban aspirin therapy) after lower extremity revascularization.
- Trial name
- CVAALR (NCT04168398)
- Testing
- Combination drug
- Where
- Egypt
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2
The investigators study aims to test the correlation between the Hemochron Signature point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 2 (NCT02371070)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen